Biomarin Pharmaceutical (BMRN) Beats Q2 Earnings Estimates by $0.28

Company Overview

Biomarin Pharmaceutical's stock moved following the earnings release. The stock currently trades at $61.46 with a market capitalization of $10.2B.

Biomarin Pharmaceutical's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.

The 30% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.

Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Biomarin Pharmaceutical should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.

Biomarin Pharmaceutical Earnings History

Quarter	EPS Actual	EPS Est.	Surprise
Q2 (Aug 2026)	$1.20	$0.92	+30.4%
Q1 (May 2026)	$0.76	$0.89	-14.6%
Q4 (Feb 2026)	$0.46	$0.36	+27.8%

Related Tools: Earnings Calendar | View BMRN Stock Page